… dopa-responsive dystonia. Over time, most patients develop early and marked levodopa-induced motor fluctuations and … of aggregates of the protein alpha-synuclein). Moreover, researchers debate vividly whether heterozygous mutations … our understanding of the biology of these proteins into specific therapies and biomarkers for future trials, we …

… Objective/Rationale: Critical research roadblocks hinder our ability to identify genetic … Similarly, definitive studies to identify the cause and early indicators of Parkinson’s disease require very large … Genome Service enables individuals to gain deeper insights into their ancestry and inherited traits. Through the …

… and that have potential to improve motor symptoms in both early and advanced stages of the disease. It is important to … than could be achieved with either drug alone. Impact on Diagnosis/Treatment of Parkinson’s Disease: If these and … to support advancing an mGlu4 activator drug candidate into testing in PD patients. Final Outcome The goals of this …

… on gene expression in diverse brain cell types. Impact on Diagnosis/Treatment of Parkinson’s disease:  These studies … Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies …

… frequency with which the drugs should be given. Impact on Diagnosis/Treatment of Parkinson’s disease:  This approach … Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies …

… and in animals that do not display PD pathology. Impact on Diagnosis/Treatment of Parkinson’s disease:  The development … Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies …